Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?

ADHD Attention Deficit and Hyperactivity Disorders

Volumn 5, Issue 2, 2013, Pages 71-81

  Gerlach, Manfred ^a   Grünblatt, Edna ^b   Lange, Klaus W ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

ADHD; Amphetamine; Dopamine neurotoxicity; Dopamine transporter; Methylphenidate; Parkinson's disease

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; DOPAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL TRIAL (TOPIC); DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SENSITIZATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBSTANCE ABUSE; TREATMENT DURATION;

AMPHETAMINE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINERGIC NEURONS; HUMANS; METHYLPHENIDATE;

EID: 84877318949     PISSN: 18666116     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-013-0105-y     Document Type: Review

References (55)

1. AACCP Official Action (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(Suppl 2): 26S-49S.
2. Advokat C (2007) Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Attent Disord 11(1): 8-16.
3. Arnold LE (2000) Methylphenidate versus amphetamine: a comparative review. In: Greenhill LL, Osman BB (eds) Ritalin, theory and practice. Mary Ann Liebert, New Rochelle, pp 127-139.
4. Bock N, Gerlach M, Rothenberger A (2010) Postnatal brain development and psychotropic drugs. Effects on animals and animal models of depression and attention-deficit/hyperactivity disorders. Curr Pharm Design 16: 2474-2483.
5. Buchhorn R, Conzelmann A, Willaschek C, Störk D, Taurines R, Renner T (2012) Heart rate variability and methylphenidate in children with ADHD. ADHD Atten Defic Hyperact Disord 4: 85-91.
6. Christine CW, Garwood ER, Schrock LE, Austin DE, McCulloch CE (2010) Parkinsonism in patients with a history of amphetamine exposure. Mov Disord 25: 228-231.
7. Diaz Heijtz R, Kolb B, Forssberg H (2003) Short communication. Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain? Eur J Neurosci 18: 3394-3399.
8. Eriksen J, Jorgensen TN, Gether U (2010) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 113(1): 27-41.
9. Gainetdinov RR (2010) Strengths and limitations of genetic models of ADHD. ADHD Atten Defic Hyperact Disord 2: 21-30.
10. Garwood ER, Bekele W, McCulloch CE, Christine CW (2006) Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 27: 1003-1006.
11. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987-1041.
12. Gerlach M, Banaschewski T, Warnke A, Rothenberger A (2003) Ist ein Parkinson-Syndrom als Spätfolge einer Methylphenidat-Behandlung im Kindesalter möglich? Eine empirische Standortbestimmung. Nervenheilkunde 22: 80-84.
13. German CL, Hanson GR, Fleckenstein AE (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123: 288-297.
14. Gill KE, Pierre PJ, Daunais J, Bennett AJ, Martelle S, Gage HD, Swanson JM, Nader MA, Porrino LJ (2012) Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates. Neuropsychopharmacology 37(12): 2555-2565.
15. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
16. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward M, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron Am Milner TA (2007) Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviours, appetite, and stress. J Neurosci 27: 7196-7207.
17. Grünblatt E, Gerlach M (2012). Letter to the editor: methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. Plos One (http://www. plosone. org/annotation/listThread. action?root=53905).
18. Grund T, Teuchert-Noodt G, Busche A, Neddens J, Brummelte S, Moll GH, Dawirs RR (2007) Administration of oral methylphenidate during adolescence prevents suppressive development of dopamine projections into prefrontal cortex and amygdala after an early pharmacological challenge in gerbils. Brain Res 1176: 124-132.
19. Halliday G, McRitchie D, Cartwright H, Pamphlett R, Hely M, Morris J (1996) Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 3: 52-60.
20. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding Y-S (2010) Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 68(9): 854-860.
21. 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194: 47-56.
22. Huang Y-S, Tsai M-H (2011) Long-term outcomes with medications for attention-deficit hyperactivity disorder. Current status of knowledge. CNS Drugs 25: 539-554.
23. Iversen L (ed) (2006) Speed, ecstasy, ritalin. The science of amphetamines, Oxford.
24. Kuczenski R, Segal DS (1997) Effects of Methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68: 2032-2037.
25. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O (2010) The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2: 241-255.
26. Markowitz JS, Straughn AB, Patrick KS, DeVane C, Pestreich L, Lee J, Wang Y, Munitz R (2003) Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42: 393-401.
27. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16(6): 687-698.
28. Moll GH, Hause S, Ruther E, Rothenberger A, Hüther G (2001) Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 11(1): 15-24.
29. Nakashima K, Kaddoumi A, Ishida Y, Itoh Z, Taki K (2003) Determination of methamphetamine and amphetamine in abuser's plasma and hair samples with HPLC-FL. Biomed Chromatogr 17: 471-476.
30. Pearl RG, Seiden LS (1979) d-Amphetamine-induced increase in catecholamine synthesis in the corpus striatum of the rat: persistence of the effect after tolerance. J Neural Transm 44: 21-38.
31. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH (2003) Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 27: 552-559.
32. Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T (2004) Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 43: 1422-1429.
33. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD (2005) Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther 315: 91-98.
34. 18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31: 1016-1026.
35. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301.
36. Robinson TE, Camp DM (1987) Long-lasting effects of escalating doses of d-amphetamine on brain monoamines, amphetamine-induced stereotyped behaviour and spontaneous nocturnal locomotion. Pharmacol Biochem Behav 26: 821-827.
37. Roessner V, Sagvolden T, DasBanerjee T, Middleton FA, Faraone SV, Walaas SI, Becker A, Rothenberger A, Bock N (2010) Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not the same extend in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 167: 1183-1191.
38. Rash JA, Aguirre-Camacho A (2012) Attention-deficit hyperactivity disorder and cardiac vagal control: a systematic review. ADHD Atten Defic Hyperact Disord 4: 167-177.
39. Ryan LJ, Martone ME, Linder JC, Groves PM (1988) Brief communication. Continuous amphetamine administration induced tyrosine hydroxylase immunoreactive patches in the adult rat neostriatum. Brain Res Bull 21: 133-137.
40. Sadasivan S, Pond BP, Pani AK, Qu C, Jiao Y, Smeyne RJ (2012) Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS ONE 7(3): e33693m. doi: 10. 1371/journal. pone. 0033693.
41. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D (2003) Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87: 273-289.
42. Shaw P (2011) ADHD medications and cardiovascular risk: some heartening news. JAMA 306: 2723-2724.
43. Sontag TA, Tucha O, Walitza S, Lange KW (2010) Animal models of attention deficit/hyperactivity disorder (ADHD): a critical review. ADHD Atten Defic Hyperact Disord 2: 1-20.
44. Soto PL, Wilcox KM, Zhou Y, Ator NA, Riddle MA, Wong D, Weed MR (2012) Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system development. Neuropsychopharmacology 37: 2566-2579.
45. Stopper H, Walitza S, Warnke A, Gerlach M (2008) Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. J Neural Transm 115: 331-334.
46. Swanson JM, Volkow ND (2001) Pharmacokinetic and pharmacodynamic properties of methylphenidate in humans. In: Solanto MV, Arnsten AFT, Castellanos FX (eds) Stimulant drugs and ADHD. Oxford University Press, Oxford, pp 259-282.
47. Swanson JM, Volkow ND (2003) Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 27: 615-621.
48. Taylor KM, Snyder SH (1974) Amphetamine: differentiation by d and l isomers of behaviour involving brain norepinephrine or dopamine. Science 168: 1487-1489.
49. Volkow ND (2012) Long-term safety of stimulant use for ADHD: findings from nonhuman primates. Neuropsychopharmacology 37: 2551-2552.
50. Volkow ND, Insel TR (2003) Editorial. What are the long-term effects of methylphenidate treatment? Biol Psychiatry 54: 1307-1309.
51. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding Y-S, Hitzemann R, Pappas N (1999) Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65: PL7-12.
52. Volkow ND, Wang G-J, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y-S, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human bran. J Neurosci 21: RC121(1-5).
53. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, Gatley SJ, Pappas N, Wong C, Vaska P, Zhu W, Swanson JM (2004) Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161: 1173-1180.
54. Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M (2007) Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm 72(Suppl): 311-315.
55. Yuan J, McCann U, Ricaurte G (1997) Methylphenidate and brain dopamine neurotoxicity. Brain Res 767: 172-175.